Imprint Wealth LLC Has $416,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Imprint Wealth LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 41.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,411 shares of the medical research company’s stock after acquiring an additional 416 shares during the period. Imprint Wealth LLC’s holdings in Amgen were worth $416,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Southland Equity Partners LLC lifted its position in Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after buying an additional 34 shares in the last quarter. Acropolis Investment Management LLC grew its stake in Amgen by 3.5% in the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after buying an additional 34 shares during the last quarter. Opal Wealth Advisors LLC grew its stake in Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after buying an additional 34 shares during the last quarter. FORVIS Wealth Advisors LLC grew its position in Amgen by 1.4% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock worth $743,000 after purchasing an additional 35 shares during the last quarter. Finally, Evanson Asset Management LLC grew its position in Amgen by 2.1% in the 4th quarter. Evanson Asset Management LLC now owns 1,666 shares of the medical research company’s stock worth $480,000 after purchasing an additional 35 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock traded down $0.57 during trading hours on Tuesday, reaching $264.94. 579,238 shares of the stock were exchanged, compared to its average volume of 2,851,632. The stock has a 50 day moving average of $279.63 and a two-hundred day moving average of $281.52. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The company has a market cap of $141.99 billion, a P/E ratio of 21.26, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same period last year, the company posted $4.09 EPS. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. Equities analysts expect that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.40%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMGN. Oppenheimer reiterated an “outperform” rating and set a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Raymond James initiated coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating for the company. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and upped their price target for the company from $264.00 to $320.00 in a report on Thursday, December 21st. Finally, StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Ten equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $295.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.